Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device ConferenceGlobeNewsWire · Oct 9, 2026
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement DisordersGlobeNewsWire · Oct 5, 2026
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Stock Has Average Price Target of $10.00Defense World · Sep 30, 2026
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026GlobeNewsWire · Sep 3, 2026
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434GlobeNewsWire · Aug 12, 2026
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth ConferenceGlobeNewsWire · Aug 6, 2026Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 28, 2026 | -$0.12 | -$0.05 | Beat |
| Feb 25, 2026 | -$0.25 | -$0.42 | Miss |
| Aug 28, 2025 | -$0.56 | -$0.34 | Beat |
| Feb 28, 2025 | -$0.69 | -$0.57 | Beat |
| Feb 3, 2025 | – | -$0.00 | |
| Aug 29, 2024 | -$0.07 | -$0.80 | Miss |